Stereoselectivity in drug metabolism: Molecular mechanisms and analytical methods

Current Drug Metabolism

Volumn 10, Issue 2, 2009, Pages 188-205

  Campo, Vanessa L ^a   Bernardes, Lílian S C ^a   Carvolho, Ivone ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Analyticaltechniques; Cytochrome P450; Drug metabolism; Enantiomers; Stereoselectivity; Sulfotransferases; UDP glucuronosyltransferases

Indexed keywords

AMISULPRIDE; ARYL SULFOTRANSFERASE; ARYLPROPIONIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 2C9; FLURBIPROFEN; GALLOPAMIL; GLUCURONOSYLTRANSFERASE; MICAFUNGIN; NELARABINE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYSACCHARIDE; PROPAFENONE; PROPRANOLOL; RAMELTEON; RANOLAZINE; RASAGILINE; SALBUTAMOL; SULFINPYRAZONE; SULFOTRANSFERASE; TERBUTALINE; TIGECYCLINE; TIPRANAVIR; UNINDEXED DRUG; VERAPAMIL; VORICONAZOLE; WARFARIN;

ANALYTIC METHOD; ANGINA PECTORIS; ASTHMA; CAPILLARY ELECTROPHORESIS; CARBOHYDRATE ANALYSIS; CARDIOVASCULAR DISEASE; CHIRALITY; CRYSTAL STRUCTURE; DRUG DETERMINATION; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG ISOLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SULFATION; DRUG TRANSFORMATION; ENZYME MECHANISM; ENZYME METABOLISM; ENZYME SUBSTRATE COMPLEX; FIRST PASS EFFECT; GAS CHROMATOGRAPHY; HEART ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; INFLAMMATION; NEGATIVE SYNDROME; PAIN; POSITIVE SYNDROME; PROTEIN ANALYSIS; REVIEW; STEREOCHEMISTRY; SUPRAVENTRICULAR TACHYCARDIA;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ELECTROPHORESIS, CAPILLARY; GLUCURONOSYLTRANSFERASE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; STEREOISOMERISM; SULFOTRANSFERASES;

EID: 65549171434     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009787522188     Document Type: Review

References (150)

1. Brocks, D.R. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics. Biopharm. Drug Dispos., 2006, 27, 387-406.
2. Lu, H. Stereoselectivity in drug metabolism. Expert. Opin. Drug Metab. Toxicol., 2007, 3(2), 149-158.
3. McConathy, J.; Owens, M.J. Stereochemistry and drug action. Primary Care Companion J. Clin Psychiatry, 2003, 5(2), 70-73.
4. Rentsh, K.M. The importance of stereoselective determination of drugs in the clinical laboratory. J. Biochem. Biophys. Methods, 2002, 54, 1-9.
5. http://www.fda.gov
6. Caldwell, J. Importance of stereospecific bioanalytical monitoring in drug development. J. Chromatogr. A, 1996, 719, 3-13.
7. Bonato, P.S.; Jabor, V.A.P. Análise enantiosseletiva de fármacos: contribuições da cromatografia líquida de alta eficiência e eletroforese capilar. Quim. Nova, 2005, 28(4), 683-691.
8. Jamali, F.; Mehvar, R.; Pasutto, M. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J. Pharm. Sci., 1989, 78(9), 695-715.
9. Bermudez, J.; Barragat, P. Medicamentos quirais: da dimensão química à discussão política.Cad. Saúde Públ., 1996, 12(1), 47-51.
10. Williams, D.A.; Lemke, T.L. Foye's Principles of Medicinal Chemistry, 6th ed.; Williams & Wilkins: USA, 2002.
11. Patrick, G.L. An Introduction to Medicinal Chemistry, 3rd ed.; Oxford University Press: New York, 2005.
12. Hebert, M.F.; Townsend, R.W.; Austin, S.; Balan, G.; Blough, D.K.; Buell, D.; Keirns, J.; Bekersky, I. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol., 2005, 45, 954-960.
13. Pharm, D.S.; Matthews, J. Entecavir for the treatment of chronic hepatitis B virus infection. Clinical Therapeutics, 2006, 28(2), 184-203.
14. Rose, W.; Rybak, M. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy, 2006, 26(8), 1099-110.
15. Morello, J.; Rodriguez-Novoa, S.; Jimenez-Nacher, I.; Soriano, V. Drug interactions of tipranavir, a new HIV protease inhibitor. Drug Metabolism Letters, 2007, 1(1), 81-84.
16. Borja, N.L.; Daniel, K.L. Ramelteon for the treatment of insomnia. Clinical Therapeutics, 2006, 28(10), 1540-1555.
17. Cohen, M.H.; Johnson, J.R.; Justice, R.; Pazdur, R. FDA drug approval summary: Nelarabine (Arranon®) for the treatment of T-cell lymphoblastic leukemia/lymphoma. The Oncologist, 2008, 13(6), 709-714.
18. Chaitman, B.R. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation, 2006, 113(20), 2462-2472.
19. Rivkin, A.; Chagan, L. Lubiprostone: chloride channel activator for chronic constipation. Clinical Therapeutics, 2006, 28(12), 2008-2021.
20. Patterson, T.; Boucher, H.; Herbrecht, R.; Denning, D.; Lortholary, O.; Ribaud, P.; Rubin, R.; Wingard, J.; DePauw, B.; Schlamm, H.; Troke, P.; Bennett, J. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis., 2005, 41(10), 1448-1452.
21. Appleton, K.; Mackay, H.J.; Judson, I.; Plumb, J.A.; McCormick, C.; Strathdee, G.; Lee, C.; Barrett, S.; Reade, S.; Jadayel, D.; Tang, A.; Bellenger, K.; Mackay, L.; Setanoians, A.; Schatzlein, A.; Twelves, C.; Kaye, S.B.; Brown, R. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol., 2007, 25(29), 4603-4609.
22. Schapira, A.; Bate, G.; Kirkpatrick, P. Rasagiline. Nature Reviews, 2005, 4, 625-626.
23. Sekar, V.J.; Lefebvre, E.; Paepe, E.D.; Marez, T.D.; De Pauw, M.; Parys, W.; Hoetelmans, R.M.W. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob. Agents Chemother., 2007, 51(3), 958-961.
24. Keating, G.M. Posaconazole. Drugs, 2005, 65 (11), 1553-1567.
25. Chan, H.L.; Heathcote, E.J.; Marcellin, P. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir. A randomized trial. Ann Intern Med, 2007, 147(11), 745-754.
26. Krishnan, S.; Moncrief, S. An evaluation of the cytochrome P450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab. Dispos., 2007, 35(1), 180-184.
27. Waldmeier, F.; Glaenzel, U.; Wirz, B.; Oberer, L.; Schmid, D.; Seiberling, M.; Valencia, J.; Riviere, G-J.; End, P.; Vaidyanathan, S. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab. Dispos., 2007, 35(8), 1418-1428.
28. Jones, R.; Fritsche, T.; Sader, H.; Ross, J. Activity of retapamulin (sb-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother., 2006, 50(7), 2583-2586.
29. Cai, P.; Tsao, R.; Ruppen, M.E. Rapamycin: something old, something new, sometimes borrowed and now renewed. Drug Metab. Dispos., 2007, 35(9), 1554-1563.
30. Newman, J.H.; Kar, S.; Kirkpatrick, P. Ambrisentan, Nature Reviews, 2007, 6, 697-698.
31. Kuritzkes, D.; Kar, S.; Kirkpatrick, P. Maraviroc. Nature Reviews, 2008, 7, 15-16.
32. 14C] Doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob. Agents Chemother., 2008, 52(10), 3478-3483.
33. Goel, S.; Cohen, M.; Çomezoglu, S.N.; Perrin, L.; André F.; Ja yabalan, D.; Iacono, L.; Comprelli, A.; Ly, V.T.; Zhang, D.; Xu, C.; Humphreys, W.G.; McDaid, H.; Goldberg, G.; Horwitz, S. B.; Mani, S. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res, 2008, 14(9), 2701-2709.
34. 2-receptor antagonists cimetidine and ranitidine. Br J Clin Pharmacol., 1997, 43(2), 201-204.
35. De Martinis, N.A.; Yeung, P.P.; Entsuah, R; Manley, A.L. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry, 2007, 68(5), 677-688.
36. Holzer, P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs, 2007, 16(2), 181-94.
37. Curran, M.P.; Robyns, G.W.; Scott, L.J.; Perry, C.M. Alvimopan. Drugs, 2008, 68(14), 2011-2019.
38. 2+ channel blocker. Expert Opin Investig Drugs, 2007, 16(9), 1449-1457.
39. Caldwell, J. Stereochemical determinants of the nature and consequences of drug metabolism. J. Chromatogr. A, 1995, 694, 39-48.
40. Testa, B. Substract and product. stereoselectivity in monooxigenase-mediated drug. activation and inactivation. Biochem. Pharmacol., 1988, 37(1), 85-92.
41. Eichelbaum, E. Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Biochem. Pharmacol., 1988, 37(1), 93-96.
42. Testa, B.; Mayer, J.M. Stereoselective drug metabolism and its significance in drug research. Prog. Drug. Res., 1988, 32, 249-303.
43. Silverman, R.B. The Organic Chemistry of Enzyme-Catalyzed Reactions, 1st ed.; Academic Press: USA, 2000.
44. Denisov, I.G.; Makris, T.M.; Sligar, S.G.; Schlichting, I. Structure and chemistry of cytochrome P450. Chem. Rev., 2005, 105, 2253-2277.
45. Nemeroff, C.B.; DeVane, C.L.; Pollock, B.G. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry, 1996, 153, 311-320.
46. Miners, J.O.; Birkett, D.J. Cytochrome P4502C9: an enzyme of major importance in drug metabolism. Br. J. Clin. Pharmacol., 1998, 45(6), 525-538.
47. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 1994, 270, 414-423.
48. Hamman, M.A.; Thompson, G.A.; Hall, S.D. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem. Phamacol., 1997, 54(1), 33-41.
49. Miners, J.O.; Coulter, S.; Tukey, R.H.; Veronese, M.E.; Birkett, D.J. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem. Phamacol, 1996, 51(8), 1003-1008.
50. Yamazaki, H.; Inoue, K.; Chiba, K.; Ozawa, N.; Kawai, T.; Suzuki, Y.; Goldstein, J.A.; Guengerich, F.P.; Shimada, T. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys-and Leu- variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes- warfarin as a probe. Biochem. Pharmacol., 1998, 56(2), 243-251.
51. Komatsu, K.; Ito, K.; Nakajima, Y.; Kanamitsu, S.I.; Imaoka, S.; Funae, Y.; Green, C.E.; Tyson, C.A.; Shimada, N.; Sugiyama, Y. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab. Dispos., 2000, 28, 475-481.
52. Giancarlo, G.M.; Venkatakrishnan, K.; Granda, B.W.; Von Moltke, L.L.; Greenblatt, D.J. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur. J. Clin. Pharmacol., 2001, 57(1), 31-36.
53. Miners, J.O.; Rees, D.L.P.; Valente, L.; Veronese, M.E.; Birkett, D.J. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. J. Pharmacol. Exp. Ther., 1995, 272, 1076-1081.
54. Usmani, K.A.; Karoly, E.D.; Hodgson, E.; Rose, R.L. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily. Drug Metab. Dispos., 2004, 32(3), 333-339.
55. Shapiro, S. Warfarin sodium derivative: (coumadin® sodium): an intravenous hypoprothrombinemia-inducing agent. Angiology, 1953, 4, 380-390.
56. Kaminski, L.S.; Zhang, Z.Y. Human P450 metabolism of warfarin. Pharmacol. Ther., 1997, 73(1), 67-74.
57. Kaminsky, L.S. Warfarin as a probe of cytochrome P-450 function. Drug Metab. Rev., 1989, 20, 479-487.
58. Trager, W.F. Stereochemistry of cytochrome P-450 reactions. Drug Metab. Rev., 1989, 20, 489-496.
59. www.rcsb.org/pdb
60. Williams, P.A.; Cosme, J.; Ward, A.; Angove, H.C.; Vinkovic, D.M.; Jhoti, H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 2003, 424, 464-468.
61. Haines, D.C.; Tomchick, D.R.; Machius, M.; Peterson, J.A. Pivotal role of water in the mechanism of P450-BM3. Biochemistry, 2001, 40, 13456-13465.
62. Modi, S.; Sutcliffe, M.J.; Primrose, W.U.; Lian, L.Y.; Roberts, G.C. The catalytic mechanism of cytochrome P450 BM3 involves a 6 Å movement of the bound substrate on reduction. Nature Struct. Biol., 1996, 3, 414-417.
63. Modi, S.; Sutcliffe, M.J.; Primrose, W.U.; Lian, L.Y.; Roberts, G.C. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: Allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry, 1997, 36, 4461-4470.
64. Kantor, T.G. Physiology and treatment of pain and inflammation: analgesic effects of flurbiprofen. Am. J. Med., 1986, 80(Suppl 3A), 3-9.
65. Risdall, P.C.; Adams, S.S.; Crampton, E.L. Marchant, B. The disposition and metabolism of flurbiprofen in several species including man. Xenobiotica, 1978, 8, 691-704.
66. Knadler, M.P.; Hall, S.D. Analysis of the enantiomers of flurbiprofen and its metabolites in plasma and urine. J. Chromatogr. Biomed. Appl., 1989, 494, 173-182.
67. Szpunar, G.J.; Albert, K.S.; Bole, G.G.; Dreyfus, J.N.; Lockwood, G.F.; Wagner, J.G. Pharmacokinetics of flurbiprofen in man. I. Area/dose relationships. Biopharm. Drug. Dispos., 1987, 8, 273-283.
68. Sykes, M.J.; McKinnon, R.A.; Miners, J.O. Alignment and docking studies of seventy CYP2C9 substrates using the shape and chemistry of flurbiprofen as a template. J. Med. Chem., 2008, 51(4), 780-791.
69. Wester, M.R.; Yano, J.K.; Schoch, G.A.; Yang, C.; Griffin, K.J.; Stout, C.D.; Johnson, E.F. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0 Å resolution. J. Biol. Chem., 2004, 279(34), 35630-35637.
70. Tukey, R.H.; Strassburg, C.P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol., 2000, 40, 581-616.
71. King, C.D.; Rios, G.R.; Green, M. D.; Tephly, T.R. UDP-glucuronosyltransferases. Curr. Drug Metab., 2000, 1, 143-161.
72. Miley, M.J.; Zielinska, A.K.; Keenan, J.E.; Bratton, S.M.; Radominska-Pandya, A.; Redinbo, M.R. Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J. Mol. Biol., 2007, 369(2), 498-511.
73. Samokyszyn, V.M.; Gall, W.E.; Zawada, G.; Freyaldenhoven, M.A.; Chen, G.; Mackenzie, P.I. 4-hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2BT. J. Biol. Chem., 2000, 275(10), 6908-6914.
74. Sten, T.; Qvisen, S.; Uutela, P.; Luukkanen, L.; Kostiainen, R.; Finel, M. Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and 1A10. Drug Metab. Dispos., 2006, 34(9), 1488-1494.
75. Radominska-Pandya, A; Pokrovskaya, I.D.; Xu, J.; Little, J.M.; Jude, A.R.; Kurten, R.C.; Czernik, P.J. Nuclear UDP-glucuronosyltransferases: identification of UGT2B7 and UGT1A6 in human liver nuclear membranes. Arch. Biochem. Biophys., 2002, 399(1), 37-48.
76. Operana, T.N.; Tukey, R.H. Oligomerization of the UDP-glucuronosyltransferase 1A proteins: Homo- and heterodimerization analysis by fluorescence resonance energy transfer and coimmunoprecipitation. J. Biol. Chem., 2007, 282(7), 4821-4829.
77. Silber, B.; Holford, N.H; Riegelman, S. Stereoselective disposition and glucuronidation of propranolol in human. J. Pharm. Sci., 1982, 71(6), 699-704.
78. Walle, T.; Walle U.K.; Olanoff, L.S. Quantitative account of propranolol metabolism in urine of normal man. Drug Metab. Dispos., 1985, 13(2), 204-209.
79. Coffman, B.L.; King, C.D.; Rios, G.R.; Tephly, T.R. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos., 1998, 26(1), 73-77.
80. Li, X.; Yu, Y.N.; Zhu, G.J.; Qian, Y.L. Cloning of UGT1A9 cDNA from liver tissues and its expression in CHL cells. World J. Gastroenterol., 2001, 7(6), 841-845.
81. Luan, L.; Shao, Q.; Ma, J.Y.; Zeng, S. Stereoselective urinary excretion of S-(-) and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in chinese Han subjects. World J. Gastroenterol., 2005, 11(12), 1822-1824.
82. Glatt, H. Sulfotransferases in the bioactivation of xenobiotics. Chem. Biol. Interact., 2000, 129, 141-170.
83. Blanchard, R.L.; Freimuth, R.R.; Buck, J.; Weinshilboum, R.M.; Coughtrie, M.W. A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily. Pharmacogenetics, 2004, 14(3), 199-211.
84. Wang, J.; Falany, J.L.; Falany, C.N. Expression and characterization of a novel thyroid hormone-sulfating form of cytosolic sulfotransferase from human liver. Mol. Pharmacol., 1998, 53(2), 274-282.
85. Her, C.; Kaur, G.P.; Athwal, R.S.; Weinshilboum, R.M. Human sulfotransferase SULT1C1: cDNA cloning, tissue-specific expression, and chromosomal localization. Genomics, 1997, 41(3), 467-470.
86. Morgan, D.J. Clinical pharmacokinetics of β-agonists. Clin. Pharmacokinet., 1990, 18(4), 270-294.
87. Sanjar, S.; Kristersson, A.; Mazzoni, L.; Morley, J.; Schaeublin, E. Increased airway reactivity in the guinea-pig follows exposure to intravenous isoprenaline. J. Physiol., 1990, 425, 43-54.
88. Chapman, I.D.; Buchheit, K.H.; Manley, P.; Morley, J. Active enantiomers may cause adverse effects in asthma. Trends Pharmacol. Sci., 1992, 13(6), 231-232.
89. Lin, C.; Li, Y.; McGlotten, J.; Morton, J.B.; Symchowicz, S. Isolation and identification of the major metabolite of albuterol in human urine.Drug Metab. Dispos., 1977, 5(3), 234-238.
90. Pesola, G.R.; Walle, T. Enantiomeric interaction in the sulfate conjugation of the beta 2-agonist drug albuterol by the human liver. Res. Commun. Chem. Pathol. Pharmacol., 1992, 75(1), 125-128.
91. Walle, U.K.; Pesola, G.R.; Walle, T. Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity. Br. J. Clin. Pharmacol., 1993, 35(4), 413-418.
92. Walle, T.; Walle, U.K.; Thornburg, K.R.; Schey, K.L. Stereoselective sulfation of albuterol in humans. Biosynthesis of the sulfate conjugate by HEP G2 cells. Drug Metab. Dispos., 1993, 21, 76-80.
93. Walle, T.; Walle, U.K. Stereoselective sulphate conjugation of racemic terbutaline by human liver cytosol. Br. J. Clin. Pharmacol., 1990, 30(1), 127-133.
94. Adams, S.S; Bresloff, P.; Mason, C.G. Pharmacological differences between the optical isomers of ibuprofen: evidence for metabolic inversion of the (-)-isomer. J. Pharm. Pharmacol., 1976, 28, 256-257.
95. Hutt, A.J.; Caldwell, J. The importance of stereochemistry in the clinical pharmacokinetics of the 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. Clin. Pharmacokinet., 1984, 9, 371-373.
96. Kean, W.F.; Lock, C.J.L.; Rischke, J.; Butt, R.; Buchanan, W.W.; Howard-Lock, H. Effect of R and S enantiomers of naproxen on aggregation and thromboxane production in human platelets. J. Pharm. Sci., 1989, 78(4), 324-327.
97. Mohri, K.; Okada, K.; Benet, L.Z. Stereoselective taurine conjugation of (R)-benoxaprofen enantiomer in rats: in vivo and in vitro studies using rat hepatic mitochondria and microsomes. Pharm Res., 2005, 22(1), 79-85.
98. Brocks, D.R.; Jamali, F. In The Pharmacokinetics of Ibuprofen in Humans and Animals; Rainsford K.D., Ed.; Taylor and Francis: Philadelphia, 1999, Vol. 1, pp. 87-143.
99. Smith, D.A. Pharmacokinetics and pharmacodynamics in toxicology. Xenobiotica, 1997, 27(5), 513-525.
100. Soucek, P.; Gut, I. Cytochromes P-450 in rats: structures, functions, properties, and relevant human forms. Xenobiotica, 1992, 22(1), 83-103.
101. Kroemer, H.K.; Fromm, M.F.; Eichelbaum, M. Stereoselectivity in drug metabolism and action: effects of enzyme inhibition and induction. Ther. Drug Monit., 1996, 18(4), 388-392.
102. Toon, S.; Low, L.K.; Gibaldi, M. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin. Pharmacol. Ther., 1986, 39(1), 15-24.
103. Takahashi, H.; Sato, T.; Shimoyama, Y.; Shioda, N.; Shimizu, T.; Kubo, S.; Tamura, N.; Tainaka, H.; Yasumori, T.; Echizen, H.; Echizen, H. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin. Pharmacol. Ther., 1999, 66(6), 569-581.
104. Gibaldi, M. Stereoselective and isozyme-selective drug interactions. Chirality, 1993, 5, 407-413.
105. Kroemer, H.K.; Funck-Brentano, C.; Silberstein, D.J.; Wood, A.J.J.; Eichelbaum, M.; Woosley, R.L.; Roden, D.M. Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation, 1989, 79, 1068-1076.
106. Stoschitzky, K.; Klein, W.; Stark, G.; Stark, U.; Zernig, G.; Graziadei, I.; Lindner, W. Different stereoselective effects of (R)- and (S)-propafenone: clinical, pharmacologic, electrophysiologic, and radioligand binding studies. Clin. Pharmacot Ther., 1990, 47, 740-746.
107. Kroemer, H.K.; Fischer, C.; Meese, C.O.; Eichelbaum, M. Enantiomer/ enantiomer interaction of (S)- and (R)-propafenone for cytochrome P45011D6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism. Mol. Pharmacol., 1991, 40,135-142.
108. Echizen, H.; Manz, M.; Eichelbaum, M. Electrophysiologic effects of detro- and levo-verapamil on sinus node and AV node function in humans. J. Cardiovasc. Pharmacol., 1988, 12, 543-546.
109. Echizen, H.; Vogelgesang, B.; Eichelbaum, M. Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin. Pharmacol. Ther., 1985, 38, 71-76.
110. Hadley, M.R.; Camiller, P.; Hutt, A.J. Enantiospecific analysis by capillary electrophoresis: applications in drug metabolism and pharmacokinetics. Electrophoresis, 2000, 21, 1953-1976.
111. Pirkle W.H.; Pochapsky T.C. In Advances in Chromatography; Giddings J.C.; Grushka E.; Brown P.R., Eds.; Marcel Dekker Inc.: New York, 1987; Vol 27, pp. 73-127.
112. Levin, S.; Abu-Lafi, S. In Advances in Chromatography; Grushka, E.; Brown, P. R., Eds.; Marcel Dekker Inc.: New York, 1993; Vol. 33, pp. 233-266.
113. Yashima, E. Polysaccharide-based chiral stationary phases for high-performance liquid chromatographic enantioseparation. J. Chromatogr. A, 2001, 906, 105-125.
114. Bonato, P.S.; Bortocan, R.; Gaitani, C.M.; Paiasb, F.O.; Iha, M.H.; Lima, R.P. Enantiomeric resolution of drugs and metabolites in polysaccharide- and protein-based chiral stationary phases. J. Braz. Chem. Soc., 2002, 13(2), 190-199.
115. Fornstedt, T.; Sajonz, P.; Guiochon, G. A closer study of chiral retention mechanisms. Chirality, 1998, 10, 375-381.
116. Hesse, G.; Hagel, R. Complete separation of a racemic mixture by elution chromatography on cellulose triacetate. Chromatographia, 1973, 6, 277-280.
117. Ichida, A.; Shibata, T.; Okamoto, I.; Yuki, Y.; Namikoshi, H.; Toga, Y. Resolution of enantiomers by HPLC on cellulose derivatives. Chromatographia, 1984, 19, 280-284.
118. Shibata, T.; Sei, T.; Nishimura, H.; Deguchi, K. Hysteretic effect of the coating solvent on chiral recognition by cellulose derivative. Chromatographia, 1987, 24, 552-554.
119. Wainer, I.W. In Drug Stereochemistry: Analytical Methods and Pharmacology; Wainer, I.D., Ed.; Marcel Dekker: New York, 1993; Vol. 1, pp. 139-160.
120. Millot, M.C. Separation of drug enantiomers by liquid chromatography and capillary electrophoresis, using immobilized proteins as chiral selectors. J. Chromatogr., B: Biomed. Sci. Appl., 2003, 797, 131-159.
121. Haginaka, J. Protein-based chiral stationary phases for high-performance liquid chromatography enantioseparations. J. Chromat. A, 2001, 906(1), 253-273.
122. Wainer, I.W.; Jadaud, P.; Schombaum, G.R.; Kadodkar, S.V.; Henry, M.P. Enzymes as HPLC stationary phases for chiral resolutions-initial investigations with alphachymotrypsin. Chromatographia, 1988, 25, 903-907.
123. Allenmark, S. Chiral Separations By HPLC: Applications To Pharmaceutical Compounds, 1st ed.; Ellis Horwood: Chichester, 1989.
124. Marzo, A.; Balant, L.P. Investigation of xenobiotic metabolism by CYP2D6 and CYP2C19: importance of enantioselective analytical methods. J. Chromatogr. B, 1996, 678(1), 73-92.
125. Hermansson, J.; Von Bahr, C. Determination of (R)-and (S)-alprenolol-and (R)- and (S)-metoprolol as their diastereomeric derivatives in human plasma by reversed-phase liquid chromatography. J. Chromatogr., 1982, 227(1), 113-127.
126. Lennard, M.S.; Tucker, G.T.; Silas, J.H.; Freestone, S.; Ramsay, L.E.; Woods, H.F. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin. Pharmacol. Ther., 1983, 34(6), 732-737.
127. Aubry A.F.; Markoglou N.; Descorps V.; Wainer I.W.; Felix G. Evaluation of a chiral stationary phase based on mixed immobilized proteins. J. Chromatogr. A, 1994, 685(1), 1-6.
128. Vandenbosch, C.; Massart, D.L.; Lindner, W. Evaluation of 6 chiral stationary phases in LC for their selectivity towards drug enantiomers. J. Pharm. Biomed. Anal., 1992, 10(10), 895-980.
129. 1-acid glycoprotein-based chiral stationary phase. J. Chromatogr. A, 1997, 760(19), 193-203.
130. Gaitani, C. M.; Lanchote, V. L.; Bonato, P. S. Enantioselective analysis of propafenone in plasma using a polysaccharide-based chiral stationary phase under reversed-phase conditions. J. Chromatogr. B, 1998, 708(1), 177-183.
131. Mehvar, R. Liquid chromatographic analysis of propafenone enantiomers in human plasma. J. Chromatogr., 1990, 527(1), 79-89.
132. Kern, R. Internally standardized simultaneous assay of propafenone and 5-hydroxypropafenone enantiomers in human plasma by means of high performance liquid chromatography. Methods Find. Exp. Clin. Pharmacol., 1994, 16(3), 203-210.
133. Bohm, R.; Ellrich, R.; Koytchev, R. Quantitation of R- and S-propafenone and of the main metabolite in plasma. Pharmazie, 1995, 50(8), 542-545.
134. Hollenhorst, Th.; Blaschke, G. Direct separation of the enantiomers of propafenone, diprafenone and their metabolites by high-performance liquid chromatography on modified cellulose and amylase chiral stationary phases. J. Chromatogr., 1991, 585(2), 329-332.
135. Rustichelli, C.; Ferioli, V.; Gamberini, G. Resolution of the enantiomers of verapamil and gallopamil by chiral liquid chromatography-mass spectrometry. Chromatographia, 1997, 44(9), 477-483.
136. Fieger, H.; Blaschke, G. Direct determination of the enantiomeric ratio of verapamil, its major metabolite norverapamil and gallopamil in plasma by chiral high-performance liquid chromatography. J. Chromatogr., 1992, 575(2), 255-260.
137. Terabe, S.; Otsuka, K.; Nishi, H. Separation of enantiomers by capillary electrophoretic techniques. J. Chromatogr. A, 1994, 666(1), 295-319.
138. Bojarski, J.; Aboul-Enein, H.Y. Application of capillary electrophoresis for the analysis of chiral drugs in biological fluids. Electrophoresis, 1997, 18(6), 965-969.
139. Lloyd, D.K. In Pharmaceutical and Biomedical Applications of Liquid Chromatography, Riley, C.M.; Lough, W. J.; Wainer, I.W., Eds.; Pergamon/ Elsevier: Oxford, 1994; Vol. 1, pp. 3-40.
140. Wistuba, D.; Schurig, V. Enantiomer separation of chiral pharmaceuticals by capillary electrochromatography. J. Chromatogr. A, 2000, 875(1), 255-276.
141. Blanco, M.; Valverde, I. Choice of chiral selector for enantioseparation by capillary electrophoresis. Trends Anal. Chem., 2003, 22, 428-439.
142. Bressolle, F.; Audran, M.; Pham, T.-N.; Vallon, J.-J. Cyclodextrins and enantiomeric separations of drugs by liquid chromatography and capillary electrophoresis: basic principles and new developments. J. Chromatogr., B: Biomed. Sci. Appl., 1996, 687(2), 303-336.
143. Fanali, S. Enantioselective determination by capillary electrophoresis with cyclodextrins as chiral selectors. J. Chromatogr., A, 2000, 875(1), 89-122.
144. Wainer, I.W.; Drayer, D.E. Drug Stereochemistry. Analytical Methods and Pharmacology, 1st ed.; Marcel Dekker: New York, 1988.
145. Racagni, G.; Canonico, P.L.; Ravizza, L.; Pani, L. Amore, M. Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology, 2004, 50(2), 134-143.
146. McKeage, K.; Plosker, G.L. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs, 2004, 18(13), 933-956.
147. 2 receptors. Eur. J. Pharmacol., 2001, 432(2), 143-147.
148. Ascalone, V.; Ripamonti, M.; Malavasi, B. Stereospecific determination of amisulpride, a new benzamide derivative, in human plasma and urine by automated solid-phase extraction and liquid chromatography on a chiral column application to pharmacokinetics. J. Chromatogr. B: Biomedical sciences and application, 1996, 676(1), 95-105.
149. Musenga, A.; Mandrioli, R.; Morganti, E.; Fanali, S.; Raggi, M.A. Enantioselective analysis of amisulpride in pharmaceutical formulations by means of capillary electrophoresis. J. Pharm. Biom. Anal., 2008, 46(5), 966-970.
150. Gareli, P.; Gramond, J.P.; Guyon, F. Separation and determination of warfarin enantiomers in human plasma by capillary zone electrophoresis using a methylated beta-cyclodextrin-containing electrolyte. J. Chromatogr., 1993, 615(2), 317-325.